Page 129 - Genomic Medicine in Emerging Economies

118 CHAPTER 6: Neuropsy chiatric Genomics in Latin Americ a

predicts effectiveness of stimulant medication. Mol. Psychiatry 15 (11), 1053–1066. doi:
10.1038/mp.2010.6.
Bau, C.H., Almeida, S., Costa, F.T., Garcia, C.E., Elias, E.P., Ponso, A.C., Hutz, M.H., 2001. DRD4
and DAT1 as modifying genes in alcoholism: interaction with novelty seeking on level of alco-
hol consumption. Mol. Psychiatry 6 (1), 7–9.
Benitez, B.A., Forero, D.A., Arboleda, G.H., Granados, L.A., Yunis, J.J., Fernandez, W., Arboleda, H.,
2010. Exploration of genetic susceptibility factors for Parkinson’s disease in a South American
sample. J. Genet. 89 (2), 229–232.
Bertola, V., Cordeiro, Q., Zung, S., Miracca, E.C., Vallada, H., 2007. Association analysis between
the C516T polymorphism in the 5-HT2A receptor gene and schizophrenia. Arq Neurop-
siquiatr. 65 (1), 11–14.
Bonifaz-Pena, V., Contreras, A.V., Struchiner, C.J., Roela, R.A., Furuya-Mazzotti, T.K., Chammas, R.,
Suarez-Kurtz, G., 2014. Exploring the distribution of genetic markers of pharmacogenomics
relevance in Brazilian and Mexican populations. PLoS One 9 (11), e112640, 10.1371/journal.
pone.0112640.
Bruxel, E.M., Akutagava-Martins, G.C., Salatino-Oliveira, A., Genro, J.P., Zeni, C.P., Polanczyk,
G.V., Hutz, M.H., 2016. GAD1 gene polymorphisms are associated with hyperactivity in at-
tention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 171 (8),
1099–1104, 10.1002/ajmg.b.32489.
Bruxel, E.M., Salatino-Oliveira, A., Akutagava-Martins, G.C., Tovo-Rodrigues, L., Genro, J.P., Zeni,
C.P., Hutz, M.H., 2015. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility
and pharmacogenetic study. Genes Brain Behav. 14 (5), 419–427, 10.1111/gbb.12224.
Bruxel, E.M., Salatino-Oliveira, A., Genro, J.P., Zeni, C.P., Polanczyk, G.V., Chazan, R., Hutz, M.H.,
2013. Association of a carboxylesterase 1 polymorphism with appetite reduction in children
and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.
Pharmacogenomics J. 13 (5), 476–480, 10.1038/tpj.2012.25.
Burmeister, M., McInnis, M.G., Zollner, S., 2008. Psychiatric genetics: progress amid controversy.
Nat. Rev. Genet. 9 (7), 527–540. doi: 10.1038/nrg2381.
Burneo, J.G., Tellez-Zenteno, J., Wiebe, S., 2005. Understanding the burden of epilepsy in Latin
America: a systematic review of its prevalence and incidence. Epilepsy Res. 66 (1–3), 63–74.
doi: 10.1016/j.eplepsyres.2005.07.002.
Cajal, A.R., Redal, M.A., Costa, L.D., Lesik, L.A., Faccioli, J.L., Finkelsztein, C.A., Argibay, P.F., 2012.
Influence of 5-HTTLPR and 5-HTTVNTR polymorphisms of the serotonin transporter gene
(SLC6A4) on major depressive disorder in a sample of Argentinean population. Psychiatr.
Genet. 22 (2), 103–104. doi: 10.1097/YPG.0b013e32834acc9b.
Camelo, D., Arboleda, G., Yunis, J.J., Pardo, R., Arango, G., Solano, E., Arboleda, H., 2004. Angio-
tensin-converting enzyme and alpha-2-macroglobulin gene polymorphisms are not associ-
ated with Alzheimer’s disease in Colombian patients. J. Neurol. Sci. 218 (1–2), 47–51. doi:
10.1016/j.jns.2003.10.008.
Campos, S.B., Miranda, D.M., Souza, B.R., Pereira, P.A., Neves, F.S., Bicalho, M.A., Correa, H.,
2010. Association of polymorphisms of the tryptophan hydroxylase 2 gene with risk for bi-
polar disorder or suicidal behavior. J. Psychiatr. Res. 44 (5), 271–274. doi: 10.1016/j.jpsy-
chires.2009.09.007.
Campos, S.B., Miranda, D.M., Souza, B.R., Pereira, P.A., Neves, F.S., Tramontina, J., Correa, H.,
2011. Association study of tryptophan hydroxylase 2 gene polymorphisms in bipolar disor-
der patients with panic disorder comorbidity. Psychiatr. Genet. 21 (2), 106–111. doi: 10.1097/
YPG.0b013e328341a3a8.
Cappi, C., Muniz, R.K., Sampaio, A.S., Cordeiro, Q., Brentani, H., Palacios, S.A., Hounie, A.G.,
2012. Association study between functional polymorphisms in the TNF-alpha gene and obses-
sive-compulsive disorder. Arq Neuropsiquiatr. 70 (2), 87–90.